• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
PCRX

PCRX

Pacira BioSciences, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD22.32

+0.07 (+0.31%)

Rating:B+

Company Profile

CEO

Frank D. Lee

IPO Date

2011-02-03

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$22.28

Prev. Close

$22.25

Day Low

$22.00

Day High

$22.53

52W Low

$18.80

52W High

$27.64

Market Cap

$0.88B

Volume

0.21M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

28.5%

Avg Negative

28.9%

Avg Neutral

42.6%

News Feed

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research·7/27/2021·↑ positive

Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021

GlobeNewsWire·7/20/2021·↓ negative

Moving Average Crossover Alert: Pacira BioSciences (PCRX)

Zacks Investment Research·6/15/2021·↓ negative

Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021

GlobeNewsWire·6/8/2021·↑ positive

Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries

Benzinga·5/26/2021·↓ negative

Pacira BioSciences Looks To Reverse Current Trend, And A Huge Short Position Could Help

Seeking Alpha·5/11/2021·↓ negative

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

Zacks Investment Research·5/5/2021·↑ positive

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/4/2021·↓ negative

Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021

GlobeNewsWire·4/21/2021·↓ negative

Pacira BioSciences Announces Investment in Spine BioPharma

GlobeNewsWire·4/20/2021·↑ positive